Oncology & Cancer

Lymphoma risk up with thiopurine, anti-TNF Tx in IBD

(HealthDay)—For patients with inflammatory bowel disease (IBD), the risk of lymphoma is increased with use of thiopurine monotherapy, anti-tumor necrosis factor (TNF) monotherapy, and combination therapy, according to a ...

Oncology & Cancer

Scientists identify genetic drivers of common lymphoma

An international team of scientists has pinpointed the genetic drivers of diffuse large B-cell lymphoma—the most common type of blood cancer—and determined the genes' clinical significance. The study, published in the ...

Oncology & Cancer

Study links mutations in notch gene to role in B cell cancers

Notch is one of the most frequently mutated genes in chronic lymphocytic leukemia (CLL), the most common leukemia in adults in the United States. It is also often mutated in other common B cell tumors, such as mantle cell ...

Oncology & Cancer

PFS up with obinutuzumab-based Tx in follicular lymphoma

(HealthDay)—For patients with follicular lymphoma, obinutuzumab-based immunochemotherapy is associated with longer progression-free survival than rituximab-based therapy, according to a study published online Oct. 4 in ...

Oncology & Cancer

FDA approves aliqopa for follicular lymphoma

(HealthDay)—Aliqopa (copanlisib) has been approved by the U.S. Food and Drug Administration to treat adults with relapsed follicular lymphoma who have received at least two prior treatments with certain other drugs.

page 25 from 40